Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
PSMA
detection
diagnosis
prostate cancer
target biopsy
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
29
11
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
To assess whether a diagnostic pathway in which prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is used as a single imaging modality is feasible to guide targeted biopsy and to detect clinically significant prostate cancer (csPCa) in biopsy-naïve men at high-risk of disease. A total of 60 men with a prostate-specific antigen (PSA) level of 20-50 ng/mL underwent Lesions suspicious for PCa in the prostate gland were observed on all PSMA-PET/CTs. A total of 27/60 men (45%) already had metastatic disease on staging Using the PSMA-driven single imaging modality pathway in biopsy-naïve men at high-risk of PCa, a substantial number of diagnostic MRI scans could be avoided while at the same time obtaining adequate targeting, staging, and detection of csPCa.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Gallium Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-712Informations de copyright
© 2023 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-387
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34
Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328
Ilic D, Djulbegovic M, Jung JH et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018; 362: k3519
Mottet N, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79: 243-262
Kasivisvanathan V, Rannikko AS, Borghi M et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378: 1767-1777
Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16-40
Drost FH, Osses DF, Nieboer D et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019; 4: Cd012663
Wegelin O, van Melick HHE, Hooft L et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of In-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol 2017; 71: 517-531
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-85
Szabo Z, Mena E, Rowe SP et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015; 17: 565-574
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-Centre study. Lancet 2020; 395: 1208-1216
Perera M, Papa N, Roberts M et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2020; 77: 403-417
Perner S, Hofer MD, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701
Rahbar K, Weckesser M, Huss S et al. Correlation of Intraprostatic tumor extent with (6)(8)Ga-PSMA distribution in patients with prostate cancer. J Nucl Med 2016; 57: 563-567
Lopci E, Saita A, Lazzeri M et al. (68)Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol 2018; 200: 95-103
Berger I, Annabattula C, Lewis J et al. (68)Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 2018; 21: 204-211
Bodar Y, Jansen BHE, van der Voorn JP, Zwezerijnen GJC. Detection of prostate cancer with 18F-DFCPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. World J Urol 2020; 39: 2439-2446
Mottet N, Bellmunt J, Briers E et al. EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands: EAU Guidelines Office, 2020
D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974
Jansen BHE, Kramer GM, Cysouw MCF et al. Healthy tissue uptake of (68)Ga-prostate specific membrane antigen (PSMA), (18)F-DCFPyL, (18)F-Fluoromethylcholine (FCH) and (18)F-Dihydrotestosterone (FDHT). J Nucl Med 2019 Jan; 10: 1111-1117
Jansen BHE, Yaqub M, Voortman J et al. Simplified methods for quantification of (18)F-DCFPyL uptake in patients with prostate cancer. J Nucl Med 2019; 60: 1730-1735
Ceci F, Oprea-Lager DE, Emmett L et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 2021; 48: 1626-1638
Scheltema MJ, Chang JI, Stricker PD et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int 2019; 124(Suppl 1): 42-49
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244-252
van der Leest M, Cornel E, Israel B et al. Head-to-head comparison of Transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 2019; 75: 570-578
Ahmed HU, El-Shater Bosaily A, Brown LC et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389: 815-822
Kawada T, Yanagisawa T, Rajwa P et al. Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 2022; 5: 390-400
Emmett L, Buteau J, Papa N et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol 2021; 80: 682-689
Ferraro DA, Becker AS, Kranzbühler B et al. Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. Eur J Nucl Med Mol Imaging 2021; 48: 3315-3324